Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924

Xiaonan Hou, Fei Huang, Joan M. Carboni, Karen Flatten, Yan Asmann, Cynthia Ten Eyck, Takeo Nakanishi, Jennifer D. Tibodeau, Douglas D. Ross, Marco M. Gottardis, Charles Erlichman, Scott H Kaufmann, Paul Haluska

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Preclinical investigations have identified insulin-like growth factor (IGF) signaling as a key mechanism for cancer growth and resistance to clinically useful therapies in multiple tumor types including breast cancer. Thus, agents targeting and blocking IGF signaling have promise in the treatment of solid tumors. To identify possible mechanisms of resistance to blocking the IGF pathway, we generated a cell line that was resistant to the IGF-1R/InsR benzimidazole inhibitors, BMS-554417 and BMS-536924, and compared expression profiles of the parental and resistant cells lines using Affymetrix GeneChip Human Genome U133 arrays. Compared with MCF-7 cells, breast cancer resistance protein (BCRP) expression was increased 9-fold in MCF-7R4, which was confirmed by immunoblotting and was highly statistically significant (P = 7.13E-09). BCRP was also upregulated in an independently derived resistant cell line, MCF-7 924R. MCF-7R4 cells had significantly lower intracellular accumulation of BMS-536924 compared with MCF-7 cells. Expression of BCRP in MCF-7 cells was sufficient to reduce sensitivity to BMS-536924. Furthermore, knockdown of BCRP in MCF-7R4 cells resensitized cells to BMS-536924. Four cell lines selected for resistance to the pyrrolotriazine IGF-1R/InsR inhibitor, BMS-754807, did not have upregulation of BCRP. These data suggest that benzimidazole IGF-1R/ InsR inhibitors may select for upregulation and be effluxed by the ATP-binding cassette transporter, BCRP, contributing to resistance. However, pyrrolotriazine IGF-1R/InsR inhibitors do not appear to be affected by this resistance mechanism.

Original languageEnglish (US)
Pages (from-to)117-125
Number of pages9
JournalMolecular Cancer Therapeutics
Volume10
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Somatomedin Receptors
Insulin Receptor
Somatomedins
Breast Neoplasms
Pharmaceutical Preparations
MCF-7 Cells
Proteins
Cell Line
Up-Regulation
Neoplasms
ATP-Binding Cassette Transporters
Human Genome
BMS 536924
benzimidazole
Immunoblotting
Growth

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924. / Hou, Xiaonan; Huang, Fei; Carboni, Joan M.; Flatten, Karen; Asmann, Yan; Ten Eyck, Cynthia; Nakanishi, Takeo; Tibodeau, Jennifer D.; Ross, Douglas D.; Gottardis, Marco M.; Erlichman, Charles; Kaufmann, Scott H; Haluska, Paul.

In: Molecular Cancer Therapeutics, Vol. 10, No. 1, 01.2011, p. 117-125.

Research output: Contribution to journalArticle

Hou, Xiaonan ; Huang, Fei ; Carboni, Joan M. ; Flatten, Karen ; Asmann, Yan ; Ten Eyck, Cynthia ; Nakanishi, Takeo ; Tibodeau, Jennifer D. ; Ross, Douglas D. ; Gottardis, Marco M. ; Erlichman, Charles ; Kaufmann, Scott H ; Haluska, Paul. / Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924. In: Molecular Cancer Therapeutics. 2011 ; Vol. 10, No. 1. pp. 117-125.
@article{78623c5cd1614bd7a638195d04da3ff2,
title = "Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924",
abstract = "Preclinical investigations have identified insulin-like growth factor (IGF) signaling as a key mechanism for cancer growth and resistance to clinically useful therapies in multiple tumor types including breast cancer. Thus, agents targeting and blocking IGF signaling have promise in the treatment of solid tumors. To identify possible mechanisms of resistance to blocking the IGF pathway, we generated a cell line that was resistant to the IGF-1R/InsR benzimidazole inhibitors, BMS-554417 and BMS-536924, and compared expression profiles of the parental and resistant cells lines using Affymetrix GeneChip Human Genome U133 arrays. Compared with MCF-7 cells, breast cancer resistance protein (BCRP) expression was increased 9-fold in MCF-7R4, which was confirmed by immunoblotting and was highly statistically significant (P = 7.13E-09). BCRP was also upregulated in an independently derived resistant cell line, MCF-7 924R. MCF-7R4 cells had significantly lower intracellular accumulation of BMS-536924 compared with MCF-7 cells. Expression of BCRP in MCF-7 cells was sufficient to reduce sensitivity to BMS-536924. Furthermore, knockdown of BCRP in MCF-7R4 cells resensitized cells to BMS-536924. Four cell lines selected for resistance to the pyrrolotriazine IGF-1R/InsR inhibitor, BMS-754807, did not have upregulation of BCRP. These data suggest that benzimidazole IGF-1R/ InsR inhibitors may select for upregulation and be effluxed by the ATP-binding cassette transporter, BCRP, contributing to resistance. However, pyrrolotriazine IGF-1R/InsR inhibitors do not appear to be affected by this resistance mechanism.",
author = "Xiaonan Hou and Fei Huang and Carboni, {Joan M.} and Karen Flatten and Yan Asmann and {Ten Eyck}, Cynthia and Takeo Nakanishi and Tibodeau, {Jennifer D.} and Ross, {Douglas D.} and Gottardis, {Marco M.} and Charles Erlichman and Kaufmann, {Scott H} and Paul Haluska",
year = "2011",
month = "1",
doi = "10.1158/1535-7163.MCT-10-0438",
language = "English (US)",
volume = "10",
pages = "117--125",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924

AU - Hou, Xiaonan

AU - Huang, Fei

AU - Carboni, Joan M.

AU - Flatten, Karen

AU - Asmann, Yan

AU - Ten Eyck, Cynthia

AU - Nakanishi, Takeo

AU - Tibodeau, Jennifer D.

AU - Ross, Douglas D.

AU - Gottardis, Marco M.

AU - Erlichman, Charles

AU - Kaufmann, Scott H

AU - Haluska, Paul

PY - 2011/1

Y1 - 2011/1

N2 - Preclinical investigations have identified insulin-like growth factor (IGF) signaling as a key mechanism for cancer growth and resistance to clinically useful therapies in multiple tumor types including breast cancer. Thus, agents targeting and blocking IGF signaling have promise in the treatment of solid tumors. To identify possible mechanisms of resistance to blocking the IGF pathway, we generated a cell line that was resistant to the IGF-1R/InsR benzimidazole inhibitors, BMS-554417 and BMS-536924, and compared expression profiles of the parental and resistant cells lines using Affymetrix GeneChip Human Genome U133 arrays. Compared with MCF-7 cells, breast cancer resistance protein (BCRP) expression was increased 9-fold in MCF-7R4, which was confirmed by immunoblotting and was highly statistically significant (P = 7.13E-09). BCRP was also upregulated in an independently derived resistant cell line, MCF-7 924R. MCF-7R4 cells had significantly lower intracellular accumulation of BMS-536924 compared with MCF-7 cells. Expression of BCRP in MCF-7 cells was sufficient to reduce sensitivity to BMS-536924. Furthermore, knockdown of BCRP in MCF-7R4 cells resensitized cells to BMS-536924. Four cell lines selected for resistance to the pyrrolotriazine IGF-1R/InsR inhibitor, BMS-754807, did not have upregulation of BCRP. These data suggest that benzimidazole IGF-1R/ InsR inhibitors may select for upregulation and be effluxed by the ATP-binding cassette transporter, BCRP, contributing to resistance. However, pyrrolotriazine IGF-1R/InsR inhibitors do not appear to be affected by this resistance mechanism.

AB - Preclinical investigations have identified insulin-like growth factor (IGF) signaling as a key mechanism for cancer growth and resistance to clinically useful therapies in multiple tumor types including breast cancer. Thus, agents targeting and blocking IGF signaling have promise in the treatment of solid tumors. To identify possible mechanisms of resistance to blocking the IGF pathway, we generated a cell line that was resistant to the IGF-1R/InsR benzimidazole inhibitors, BMS-554417 and BMS-536924, and compared expression profiles of the parental and resistant cells lines using Affymetrix GeneChip Human Genome U133 arrays. Compared with MCF-7 cells, breast cancer resistance protein (BCRP) expression was increased 9-fold in MCF-7R4, which was confirmed by immunoblotting and was highly statistically significant (P = 7.13E-09). BCRP was also upregulated in an independently derived resistant cell line, MCF-7 924R. MCF-7R4 cells had significantly lower intracellular accumulation of BMS-536924 compared with MCF-7 cells. Expression of BCRP in MCF-7 cells was sufficient to reduce sensitivity to BMS-536924. Furthermore, knockdown of BCRP in MCF-7R4 cells resensitized cells to BMS-536924. Four cell lines selected for resistance to the pyrrolotriazine IGF-1R/InsR inhibitor, BMS-754807, did not have upregulation of BCRP. These data suggest that benzimidazole IGF-1R/ InsR inhibitors may select for upregulation and be effluxed by the ATP-binding cassette transporter, BCRP, contributing to resistance. However, pyrrolotriazine IGF-1R/InsR inhibitors do not appear to be affected by this resistance mechanism.

UR - http://www.scopus.com/inward/record.url?scp=78751489491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751489491&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-10-0438

DO - 10.1158/1535-7163.MCT-10-0438

M3 - Article

C2 - 21220496

AN - SCOPUS:78751489491

VL - 10

SP - 117

EP - 125

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 1

ER -